ABSTRACT RAY, JOHN G., JR. (Fort Detrick, Frederick, Md.), AND PAUL J. KADULL. Agar-gel precipitin-inhibition technique for plague antibody determinations. Appl. Microbiol. 13:925-930. 1965.-An application of the agar-gel precipitin-inhibition technique we described previously can be used to detect plague antibodies in human and animal sera after a series of plague vaccine inoculations or after exposure to Pasteurella pestis. Determination of the minimal reacting concentrations of the plague antigen and antibody reagents, methods for combining reagents, and length of incubation periods are discussed.
The agar-gel precipitin-inhibition technique of Ray and Kadull (1964) and Ray (1963) has been applied to anthrax antibody and C-reactive protein determinations, respectively, in animal and human serum specimens. This test is simply performed, has a high degree of sensitivity, and was reproducible even when employed by several technicians who were unfamiliar with the method.
This test procedure has been modified to assay antibodies for Pasteurella pestis accurately in vaccinated and infected human and animal subjects.
MATERIALS AND METHODS
Preparation of agar diffusion test plates and reading lamp. The medium test plates and agar diffusion reading lamp were prepared as described by Ray and Kadull (1964) .
P. pestis test antigen. The antigen used in this proposed serological test was obtained from outdated whole-cell formalin-killed plague vaccine, lots G 1016, G 0990, E 4649, E 9868, E 9383, and E 9135 prepared at Cutter Laboratories, Berkeley, Calif.
P. pestis test antiserum. Three rabbits were intracutaneously injected in the nape of the neck with 0.5 ml of plague Cutter vaccine at 2-day intervals for six consecutive injections. After two such courses of injections, a mean titer of 1:256 was attained when the sera were titered by this recommended technique.
Box titration of antigen and antibody system. A box titration of plague antigen versus the plague rabbit antiserum was performed in agar diffusion plates. Five serial twofold dilutions of the antigen (0.5 ml) and of the antiserum (0.2 ml) were prepared in physiological saline. To each dilution, an equivalent volume of physiological saline was added to give a final dilution range of 1:2 to 1:32.
The antigen dilutions were added sequentially and in duplicate to the two outer rows of wells (approximately 0.07-ml volume per well) so that one row exactly duplicated the opposite row in serial dilutions of antigen. This was performed in five different agar diffusion plates, one for each subsequent antiserum dilution. After incubation of the plates filled with antigen dilution for 6 hr at 37 C in an atmosphere approaching 100% humidity, the plates were removed from the incubator, and the water in the center row of reservoirs was aspirated with a pipette. Then the center row of reservoirs (approximately 0.025 ml per reservoir) was filled with one of the prepared serum dilutions; one plate was used for each dilution of antiserum.
These plates were observed with the aid of the reading lamp after incubation for 24 and 48 hr at 23 to 28 C in polyethylene bags. The end-point determination was that combination of the highest dilution of antigen and antibody that produced a visible line of precipitate lying between the center and outer rows of wells. This initial titration is essential to the establishment of maximal sensitivity and consistent reproducibility of subsequent tests with unknown sera. This end-point reading was considered to represent a minimal reacting dilution, or MRDa, of antigen, and a minimal reacting dilution, or MRDs, of antibody. This is illustrated in Outer rows of wells in an agar diffusion petri dish were sequentially filled in duplicate with the incubated antigen-antibody tube mixtures; thus, each well in one outer row contained the same mixture as the corresponding well in the opposite outer row. These plates were then placed in an incubator containing a tray of water and were incubated at 37 C for 6 hr. The water condensate was removed from the center reservoirs prior to adding the 1:8 dilution (MRD.) of known antiplague rabbit serum as determined by the box titration ( Table 1) .
The end-point titer of the unknown serum was determined after incubation in polyethylene bags at 23 to 28 C for 48 hr, with a preliminary reading at 24 hr. The titer was established as that dilution of the unknown serum that completely inhibited the formation of a visible line of precipitate
Controls consisted of dilutions of the antigen in physiological saline and combinations of the predetermined MRDa of antigen with known negative and positive antiplague sera.
RESULTS
Test sensitivity was initially determined on sera from plague-vaccinated individuals (Cutter vaccine). Numerous agglutination tests were performed on similar serum specimens without any positive indication of plague antibodies being present.
Three groups of human sera were evaluated: initial vaccine series group, booster vaccine series group, and sera from individuals who had not received any plague vaccine. The booster vaccine series group was further subdivided into a group containing sera from individuals of maximal exposure to P. pestis and a group with Table  3 .
A further analysis of antiplague antibody formation was made in four groups of five monkeys each, which were treated in the following manner. Groups A and B were vaccinated with Cutter Laboratories plague vaccine by 0.5-ml intramuscular injection on days 0, 7, and 14. On day 19, a postvaccination serum specimen was drawn for its antibody content. Then all groups (A, B, C, and D) were given a live infective dose of P. pestis intraperitoneally on day 21 after initial vaccination. Groups C and D had received no vaccine. Groups A and C monkeys received streptomycin, 15 mg per lb (0.54 kg) per day every 6 hr to 7 to 10 days, only when the individual monkey's temperature reached 105 F (40.5 C). Group B and D monkeys received no therapeutic regimen; Group D acted as the control group to the vaccinated, vaccinated-therapy, and therapy groups. All groups had a negative prevaccination titer. The results are presented in Table 4 .
Recently, an alum-adsorbed plague vaccine was administered to 14 previously immunized individuals. A prebooster serum was taken from each individual prior to the injection and a postbooster serum was obtained 21 days after the inoculation. Table 5 shows the antiplague antibody response from a booster injection of plague antigen.
In the above results, a titer increase was demonstrated in vaccinated human sera, and in vaccinated and infected monkey sera, by means of the agar-gel precipitin-inhibition serological Burmeister, Tigertt, and Overholt (1962) were assayed by this method (Table 6) . DISCUSSION The serological test procedure represents a sensitive assay of plague antibodies by inhibition of a standardized plague antigen-antibody precipitation in agar gel. It attains this sensitivity without the use of the concentrated reactants that are used in the double-diffusion technique.
The comparison of the methods in Table 2 indicates that the inhibition method is the more sensitive assay of plague antibodies. However, both methods showed a good degree of reproducibility of titer on the limited duplicated titrations of serum. The difference between the double-diffusion method shown in Table 2 (Table 3) ; this further substantiates the sensitivity of this method.
In determining the effect of vaccination and therapy in monkeys injected by the intraperitoneal route with virulent P. pestis (Table 4) , we found an increase in plague antibodies due to vaccine as well as to the live injected plague bacillus. However, only one monkey in group B, which had an immune vaccine response, survived the intraperitoneal challenge, and this monkey had the highest titer prior to challenge.
These data (Table 4) indicate that the measured antibody titer of 1:2 through 1:16 was overwhelmed by the inoculated plague challenge dose. The vaccine apparently forestalled death in these monkeys, by comparison with the postchallenge time to death of the other monkey groups. Although these group B monkeys took longer to die, indicating some modification of the disease due to the vaccine, streptomycin therapy when given early in the disease proved better than either the vaccine alone or the vaccine in combination with streptomycin therapy. Table 4 further indicates that either the vaccine does not confer immunity or not enough vaccine was given to protect the monkeys under the conditions of the test.
When an experimental alum-adsorbed plague vaccine was administered as a booster injection (Table 5) , the 21-day postbooster titer was significantly higher than those obtained in the human (Table 2) or rabbit with whole-cell formalin-killed vaccine (Table 3) .
Of more importance is the attained titer response of a human laboratory-acquired case (R.L.P.) of plague, as demonstrated in Table 6 . This case is closely analogous to the group A monkey experiment of Table 4 , with the exception that R.L.P. had a booster injection of plague vaccine (Cutter) just prior to his exposure. Both R.L.P. and the group A monkeys received immediate therapy upon developing a high temperature. The recommended test procedure adequately assayed the plague antibody content of serial serum samples in this human case and was able to detect a rise in plague titer after only 7 days of hospitalization, or approximately 12 days after the exposure to the plague bacillus.
A P. pseudotuberculosis, strain PB1 / -, prepared rabbit antiserum failed to inhibit the standardized plague antigen-antibody precipitation in agar gel. This indicated that no crossreaction occurred between this pseudotuberculosis antiserum and the plague antigen used in this serological test procedure. Although P. pseudotuberculosis and P. pestis have many antigens in common, this reaction further supports the findings of Burrows and Bacon (1960) that laboratory strains of P. pseudotuberculosis that lack the V and W antigens, as does strain PB1/ -, differ from the fully virulent P. pestis strains. However, additional VW-negative and Vpositive P. pseudotuberculosis antisera should be assayed for further substantiation of this reaction.
The recommended test procedure of agar-gel precipitin inhibition sensitively assays antibodies against the plague bacillus in vaccinated and infected human and animal serum samples.
This method does not require the use of concentrated reactants, the addition of a third entity such as complement, latex, or dye particles, nor the use of an indicator system such as chicken, goose, or sensitized sheep red blood cells.
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